Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

@article{Fisher1998TamoxifenFP,
  title={Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.},
  author={Bernard Fisher and Joseph P. Costantino and D. Lawrence Wickerham and Carol K. Redmond and Maureen T. Kavanah and Walter M. Cronin and Victor G Vogel and André Robidoux and Nikolay V. Dimitrov and James Norman Atkins and Mary Daly and Samuel Wieand and Elizabeth Tan-chiu and Leslie C. Ford and Norman Wolmark},
  journal={Journal of the National Cancer Institute},
  year={1998},
  volume={90 18},
  pages={
          1371-88
        }
}
BACKGROUND The finding of a decrease in contralateral breast cancer incidence following tamoxifen administration for adjuvant therapy led to the concept that the drug might play a role in breast cancer prevention. To test this hypothesis, the National Surgical Adjuvant Breast and Bowel Project initiated the Breast Cancer Prevention Trial (P-1) in 1992. METHODS Women (N=13388) at increased risk for breast cancer because they 1) were 60 years of age or older, 2) were 35-59 years of age with a 5… Expand

Paper Mentions

Interventional Clinical Trial
The purpose of this study is to determine the safety and usefulness of oral Vitamin D supplementation in subjects with in situ carcinoma. More specifically, this study is being… Expand
ConditionsBreast Cancer
InterventionDrug
Interventional Clinical Trial
The purpose of this study is to develop initial efficacy, feasibility, and safety data regarding the use of Tamoxifen in combination with amphotericin B and fluconazole in the… Expand
ConditionsHiv, Meningitis, Meningitis Streptococcal, (+1 more)
InterventionDrug
Interventional Clinical Trial
Based on these results it can be envisioned that the majority of endocrine-responsive post-menopausal breast cancer patients will be treated with an AI as adjuvant therapy (front… Expand
ConditionsMetastatic Breast Cancer
InterventionDrug
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
TLDR
Despite the potential bias caused by the unblinding of the P-1 trial, the magnitudes of all beneficial and undesirable treatment effects of tamoxifen were similar to those initially reported, with notable reductions in breast cancer and increased risks of thromboembolic events and endometrial cancer. Expand
The cost effectiveness of tamoxifen in the prevention of breast cancer.
TLDR
Assessment of the cost effectiveness of tamoxifen in the prevention of breast cancer in women at increased risk for developing the disease found it may be cost effective, particularly in the 35-to-49 year-old age group and in those of any age who have had a hysterectomy. Expand
The Role of Tamoxifen in Breast Cancer Prevention
TLDR
In its ongoing effort to lower the incidence of breast cancer, the NSABP is now implementing its second breast cancer prevention trial, the Study of Tamoxifen and Raloxifene (STAR), which is comparing the two agents with regard to efficacy and toxicity. Expand
National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.
TLDR
The proposed NSA BP B-35 trial will have the same design as NSABP B-24 but will compare tamoxifen with anastrozole in postmenopausal women, and outcomes will include both ipsilateral and contralateral new breast cancer and recurrences, as well as the occurrence of regional and distant disease. Expand
Tamoxifen versus raloxifene in the prevention of breast cancer.
The National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial BCPT (P-1) was designed to evaluate the value of tamoxifen in reducing the risk of invasive breastExpand
Tamoxifen for prevention of breast cancer.
  • B. Fisher
  • Medicine
  • The Medical letter on drugs and therapeutics
  • 1999
TLDR
The P-1 breast cancer prevention trial (P-1) should be viewed as more than merely a `test' of tamoxifen or an estimate of the extent of certain putative undesirable side-e€ects of the drug. Expand
Surgical Oncology Forum: Tamoxifen for the Prevention of Breast Cancer in the High-Risk Woman
TLDR
The use of tamoxifen for prevention is the culmination of more than 30 years of laboratory research that has been translated into clinical practice, and a large data base of breast cancer patients treated with tamoxIFen and followed for 10 years exists to address some of the questions suggested by the initial results of the prevention studies. Expand
Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.
TLDR
An extended follow-up of the Italian Randomized Tamoxifen Prevention Trial shows that appropriate selection of women at high risk for hormone receptor-positive (HR+) disease may improve the risk-benefit ratio of tamoxIFen intervention. Expand
Tamoxifen and risk of large bowel cancer in women with breast cancer
TLDR
The results of this large population based cohort study suggest that tamoxifen therapy may modestly increase risk of large bowel cancer in women, but only after 5 years following initiation of breast cancer therapy. Expand
The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.
TLDR
The trial will recruit a total of 22,000 postmenopausal women and is powered to demonstrate superior efficacy of either agent or their equivalence in reducing the incidence of primary breast cancer. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 76 REFERENCES
Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy.
TLDR
Analysis of the relative hazard of contralateral tumor over time showed that the benefit with tamoxifen therapy was greatest during the first 1-2 years, but there was a continued risk reduction during the entire follow-up period, i.e., more than 10 years after cessation of treatment. Expand
Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial.
TLDR
In this National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial, 1,891 women with primary operable breast cancer and positive axillary nodes were randomized to receive L-phenylalanine mustard and 5-fluorouracil either with or without tamoxifen-PFT. Expand
Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.
TLDR
The outcome of patients in the B-14 trial through 10 years of follow-up indicated that tamoxifen therapy provided substantial benefit to patients with early stage disease, and questions arose about how long the observed benefit would persist. Expand
Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.
TLDR
Risk of endometrial cancer increases following tamoxifen therapy for invasive breast cancer; however, net benefit greatly outweighs risk, and tamoxIFen treatment for breast cancer should continue. Expand
Endometrial Cancer in Tamoxifen-Treated Breast Cancer Patients: Findings From the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
TLDR
Risk of endometrial cancer increases following tamoxifen therapy for invasive breast cancer; however, net benefit greatly outweighs risk, and tamoxIFen treatment for breast cancer should continue. Expand
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
TLDR
The authors have been unable to show any effect of tamoxifen on breast-cancer incidence in healthy women, contrary to the report from the NSABP-P1 study showing a 45% reduction inhealthy women given tamoxIFen versus placebo. Expand
Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group.
TLDR
It is suggested that long-term adjuvant treatment with tamoxifen may result in substantial reduction of cardiac morbidity in patients with low risk of death from breast cancer as well as in women in chemopreventive studies who have high risk of developing breast cancer. Expand
ADJUVANT TAMOXIFEN IN THE MANAGEMENT OF OPERABLE BREAST CANCER: THE SCOTTISH TRIAL Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh
  • Medicine
  • The Lancet
  • 1987
TLDR
Improvement seems to be independent of nodal and menopausal status, and does not differ significantly with ER level, although the greatest benefit in disease-free survival is in patients with levels of 100 fmol/mg protein or more. Expand
Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women
TLDR
In this cohort of women at low-to-normal risk of breast cancer, the postulated protective effects of tamoxifen are not yet apparent and it is essential to continue follow-up to quantify the long-term risks and benefits of tamxifen therapy. Expand
...
1
2
3
4
5
...